Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy

被引:3
作者
Hearn, Andrew P. [1 ,2 ]
Hug, Oliver D. [2 ]
Somani, Ziana A. [2 ]
Kavanagh, Joanne [1 ,2 ]
d'Ancona, Grainne [1 ]
Roxas, Cris [1 ]
Green, Linda [1 ]
Thomson, Louise [1 ]
Fernandes, Mariana [1 ]
Kent, Brian D. [1 ,3 ,4 ]
Dhariwal, Jaideep [1 ]
Nanzer, Alexandra M. [1 ]
Jackson, David J. [1 ,2 ]
机构
[1] Guys & St Thomas NHS Trust, Guys Severe Asthma Ctr, Guys Hosp, London, England
[2] Kings Coll London, Sch Immunol & Microbial Sci, London SE1 9RT, England
[3] St James Hosp, Dept Resp Med, Dublin, Ireland
[4] Trinity Coll Dublin, Sch Med, Dublin, Ireland
关键词
ALLERGIC-ASTHMA; SUPER-RESPONDER; MEPOLIZUMAB; OMALIZUMAB;
D O I
10.1183/13993003.00166-2021
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
引用
收藏
页数:4
相关论文
共 14 条
[1]   Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma [J].
Bel, Elisabeth H. ;
Wenzel, Sally E. ;
Thompson, Philip J. ;
Prazma, Charlene M. ;
Keene, Oliver N. ;
Yancey, Steven W. ;
Ortega, Hector G. ;
Pavord, Ian D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13) :1189-1197
[2]   Exploring the Effects of Omalizumab in Allergic Asthma An Analysis of Biomarkers in the EXTRA Study [J].
Hanania, Nicola A. ;
Wenzel, Sally ;
Rosen, Karin ;
Hsieh, Hsin-Ju ;
Mosesova, Sofia ;
Choy, David F. ;
Lal, Preeti ;
Arron, Joseph R. ;
Harris, Jeffrey M. ;
Busse, William .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187 (08) :804-811
[3]   Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy A Randomized Trial [J].
Hanania, Nicola A. ;
Alpan, Oral ;
Hamilos, Daniel L. ;
Condemi, John J. ;
Reyes-Rivera, Irmarie ;
Zhu, Jin ;
Rosen, Karin E. ;
Eisner, Mark D. ;
Wong, Dennis A. ;
Busse, William .
ANNALS OF INTERNAL MEDICINE, 2011, 154 (09) :573-582
[4]   Biologic treatment options for severe asthma [J].
Hearn, Andrew P. ;
Kent, Brian D. ;
Jackson, David J. .
CURRENT OPINION IN IMMUNOLOGY, 2020, 66 :151-160
[5]   Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma [J].
Jackson, David J. ;
Humbert, Marc ;
Hirsch, Ian ;
Newbold, Paul ;
Garcia Gil, Esther .
ADVANCES IN THERAPY, 2020, 37 (02) :718-729
[6]   Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma [J].
Kavanagh, Joanne E. ;
Hearn, Andrew P. ;
D'Ancona, Grainne ;
Dhariwal, Jaideep ;
Roxas, Cris ;
Green, Linda ;
Thomson, Louise ;
Fernandes, Mariana ;
Kent, Brian D. ;
Nanzer, Alexandra M. ;
Jackson, David J. .
ALLERGY, 2021, 76 (06) :1890-1893
[8]   Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma [J].
Kavanagh, Joanne E. ;
d'Ancona, Grainne ;
Elstad, Maria ;
Green, Linda ;
Fernandes, Mariana ;
Thomson, Louise ;
Roxas, Cris ;
Dhariwal, Jaideep ;
Nanzer, Alexandra M. ;
Kent, Brian D. ;
Jackson, David J. .
CHEST, 2020, 158 (02) :491-500
[9]   Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma [J].
Nair, Parameswaran ;
Wenzel, Sally ;
Rabe, Klaus F. ;
Bourdin, Arnaud ;
Lugogo, Njira L. ;
Kuna, Piotr ;
Barker, Peter ;
Sproule, Stephanie ;
Ponnarambil, Sandhia ;
Goldman, Mitchell .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2448-2458
[10]  
National Institute for Health and Care Excellence Guidelines, OM TREAT SEV PERS AL